➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Mallinckrodt
Medtronic
Baxter

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Ibrexafungerp citrate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for ibrexafungerp citrate and what is the scope of freedom to operate?

Ibrexafungerp citrate is the generic ingredient in one branded drug marketed by Scynexis and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ibrexafungerp citrate has fourteen patent family members in eight countries.

Summary for ibrexafungerp citrate
International Patents:14
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
DailyMed Link:ibrexafungerp citrate at DailyMed

US Patents and Regulatory Information for ibrexafungerp citrate

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Free Forever Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Mallinckrodt
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2021 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
 NCE-1 Patent Challenge Dates 2021 - 2022
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group